Anti-TNF-α agents are currently utilised for the treatment of a vast array of autoimmune conditions including inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis and psoriasis. It is however noted that such therapeutic strategies have been linked to the specific induction of cutaneous-based reactions such as dermatitis, erythema multiforme and psoriasis. Here we present the case of a young female patient with Crohn's disease who developed psoriasis following treatment with the anti-TNF-α drug adalimumab and highlight the possible pathogenetic mechanisms involved in such an occurrence.
A 20-year-old female with extensive terminal ileal and colonic Crohn's disease was initially successfully managed on a drug regimen of prednisolone and mesalazine which helped to induce remission. The patient unfortunately however developed a mesalazine-induced aplastic anaemia. This subsequently resolved with blood product support and withdrawal of this therapy. Her thiopurine methyl transferase levels were normal, so she was commenced on azathioprine. This maintained her disease remission but was associated with neutropenic sepsis, necessitating the withdrawal of the thiopurine therapy with subsequent clinical and endoscopic disease flare. Induction and maintenance infliximab was used to regain remission. This required an infusion dose and frequency escalation to maintain clinical response. After 58 weeks of infliximab therapy, the patient was requiring 10 mg/kg 6 times weekly and hence was transferred to the fully human anti-TNF-α injection adalimumab for loss of response to infliximab. Initially this strategy regained disease control, but due to relapse at 40 mg every other week, the dose was increased step-wise to 80 mg weekly which fortunately maintained remission.
What Is the Diagnosis? Figure 1 demonstrates the presence of psoriasis which is presumed to be a result of treatment with adalimumab.
TNF-α has been identified as a key cytokine in the pro-inflammatory pathways that drive diseases such as inflammatory bowel disease and rheumatoid arthritis [1] . Anti-TNF-α agents such as infliximab and adalimumab are widely used in the treatment of these conditions and have been shown to have an impact on pro-inflammatory and apoptotic pathways. They are also effective in the treatment of the dermatological and rheumatological manifestations of psoriasis [2] . However, there have been a number of cases reported where such agents may be responsible for new onset or worsening of psoriasis. A study of 126 patients who underwent treatment with anti-TNF-α inhibitors demonstrated evidence of psoriasis in 76 individuals, palmoplantar pustular psoriasis in 37 cases and psoriasis of the nails in 6 cases [3] . There is mounting evidence that a key innate immune pathway for triggering common human autoimmune diseases, including psoriasis, involves plasmacytoid dendritic cell precursors and type 1 interferon (IFN) production. A recent study involving immunohistochemical staining of skin biopsy specimens for myxovirus-resistance protein A (MxA, a surrogate marker for lesional type 1 IFN activity) demonstrated increased staining in TNF-α inhibitor-induced psoriasis compared with psoriasis vulgaris [4] . Research suggests that a psoriasiform eruption during anti-TNF-α treatment seems to be a class effect without any confirmed predisposing factors and does not specifically require treatment discontinuation [5] . Further studies are however needed to determine the exact mechanism of and appropriate treatment for anti-TNF-α-induced psoriasis.
